These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38304196)

  • 1.
    Gao L; Xia X; Gong X; Zhang H; Sun Y
    Front Cell Infect Microbiol; 2024; 14():1296151. PubMed ID: 38304196
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Sun Y; Tan L; Yao Z; Gao L; Yang J; Zeng T
    Microbiol Spectr; 2022 Feb; 10(1):e0200721. PubMed ID: 35019705
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Gao L; Sun Y; Yuan M; Li M; Zeng T
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253207
    [No Abstract]   [Full Text] [Related]  

  • 4. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.
    Pfaller MA; Messer SA; Georgopapadakou N; Martell LA; Besterman JM; Diekema DJ
    J Clin Microbiol; 2009 Dec; 47(12):3797-804. PubMed ID: 19794038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey.
    Rambach G; Oberhauser H; Speth C; Lass-Flörl C
    Med Mycol; 2011 Nov; 49(8):856-63. PubMed ID: 21619497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
    Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
    Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
    Pfaller MA; Castanheira M; Messer SA; Jones RN
    Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination approach to treating fungal infections.
    Shrestha SK; Fosso MY; Garneau-Tsodikova S
    Sci Rep; 2015 Nov; 5():17070. PubMed ID: 26594050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triazole Evolution of Candida parapsilosis Results in Cross-Resistance to Other Antifungal Drugs, Influences Stress Responses, and Alters Virulence in an Antifungal Drug-Dependent Manner.
    Papp C; Bohner F; Kocsis K; Varga M; Szekeres A; Bodai L; Willis JR; Gabaldón T; Tóth R; Nosanchuk JD; Vágvölgyi C; Gácser A
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33115837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
    Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years.
    Pfaller MA; Carvalhaes CG; Messer SA; Rhomberg PR; Castanheira M
    Diagn Microbiol Infect Dis; 2021 Nov; 101(3):115473. PubMed ID: 34352433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efflux pump inhibitor tetrandrine exhibits synergism with fluconazole or voriconazole against Candida parapsilosis.
    Zhao YJ; Liu WD; Shen YN; Li DM; Zhu KJ; Zhang H
    Mol Biol Rep; 2019 Dec; 46(6):5867-5874. PubMed ID: 31407245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic Effect of Pyrvinium Pamoate and Azoles Against
    Sun Y; Gao L; Zhang Y; Yang J; Zeng T
    Front Microbiol; 2020; 11():579362. PubMed ID: 33224118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
    Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of Amiodarone with Azoles Against Aspergillus Planktonic Cells and Biofilms in vitro.
    Duan Z; Tong J; Zheng N; Zeng R; Liu Y; Li M
    Mycopathologia; 2022 Dec; 187(5-6):517-526. PubMed ID: 36219382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
    Castanheira M; Deshpande LM; Messer SA; Rhomberg PR; Pfaller MA
    Int J Antimicrob Agents; 2020 Jan; 55(1):105799. PubMed ID: 31520783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
    Guinea J; Peláez T; Recio S; Torres-Narbona M; Bouza E
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1396-400. PubMed ID: 18212101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole and fluconazole susceptibility of Candida isolates.
    Pelletier R; Loranger L; Marcotte H; DE Carolis E
    J Med Microbiol; 2002 Jun; 51(6):479-483. PubMed ID: 12018654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.